Brett P. Bielory
University of Miami
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Brett P. Bielory.
Acta Ophthalmologica | 2012
Brett P. Bielory; Terrence P. O’Brien; Leonard Bielory
Seasonal allergic conjunctivitis (SAC) is an inflammatory response of the conjunctiva triggered by exposure to seasonal allergens. Treatment options for SAC include artificial tears, antihistamines, decongestants, mast cell stabilizers, nonsteroidal anti‐inflammatory drugs, dual antihistamine/mast cell stabilizers, immunotherapy and corticosteroids. Topical, intranasal and systemic formulations of corticosteroids have traditionally provided the most effective relief of the inflammation and signs and symptoms associated with severe, acute exacerbations of SAC. However, steroid‐induced ocular and systemic side‐effects have limited the prescribing of these agents. This limitation of traditional corticosteroids led to the development of modified corticosteroids that retain the anti‐inflammatory mechanism of action of traditional corticosteroids with a much‐improved safety profile because of their rapid breakdown to inactive metabolites after exerting their activity. The development of one such novel corticosteroid, loteprednol etabonate (LE), led to the insertion of an ester (instead of a ketone) group at the carbon‐20 (C‐20) position of the basic corticosteroid structure. Clinical trials assessing this C‐20 ester corticosteroid have demonstrated similar efficacy to C‐20 ketone corticosteroids in the prevention or treatment of the signs and symptoms of SAC but with a greatly improved safety profile, as the C‐20 ester corticosteroid is less likely to elevate intraocular pressure. In addition, the ketone at the C‐20 position has been implicated in the formation of cataract, while nonketolic corticosteroids do not form Schiff base intermediates with lens proteins, which is a common first step in cataractogenesis. The clinical relevance of the C‐20 ester corticosteroid class, as modelled by LE, is that they provide both effective and safe treatment of the inflammation associated with SAC and relief of its signs and symptoms. Loteprednol etabonate offers a well‐tolerated treatment option for patients with debilitating acute exacerbations as well as chronic forms of the disease.
Ophthalmology | 2013
Mohamed Abou Shousha; Carol L. Karp; Ana Paula Canto; Kelly L. Hodson; Patrick Oellers; Andrew A. Kao; Brett P. Bielory; Jared L. Matthews; Sander R. Dubovy; Victor L. Perez; Jianhua Wang
PURPOSE To assess the use of ultra-high-resolution (UHR) optical coherence tomography (OCT) in the diagnosis of ocular surface lesions. DESIGN Prospective, noncomparative, interventional case series. PARTICIPANTS Fifty-four eyes of 53 consecutive patients with biopsy-proven ocular surface lesions: 8 primary acquired melanosis lesions, 5 amelanotic melanoma lesions, 2 nevi, 19 ocular surface squamous neoplasia lesions, 1 histiocytosis lesion, 6 conjunctival lymphoma lesions, 2 conjunctival amyloidosis lesions, and 11 pterygia lesions. INTERVENTION Ultra-high-resolution OCT imaging of the ocular surface lesions. MAIN OUTCOME MEASURES Clinical course and photographs, UHR OCT image, and histopathologic findings. RESULTS Ultra-high-resolution OCT images of all examined ocular surface lesions showed close correlation with the obtained histopathologic specimens. When clinical differential diagnosis of ocular surface lesions was broad, UHR OCT images provided optical signs indicating a more specific diagnosis and management. In cases of amelanotic melanoma, conjunctival amyloidosis, and primary histiocytosis and in 1 case of ocular surface squamous neoplasia, UHR OCT was instrumental in guiding the diagnosis. In those cases, UHR OCT suggested that the presumed clinical diagnosis was incorrect and favored a diagnosis that later was confirmed by histopathologic examination. CONCLUSIONS Correlations between UHR OCT and histopathologic findings confirm that UHR OCT is an adjunctive diagnostic method that can provide a noninvasive means to help guide diagnosis and management of ocular surface lesions. FINANCIAL DISCLOSURE(S) The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Immunology and Allergy Clinics of North America | 2010
Brett P. Bielory; Leonard Bielory
Atopic dermatitis, a chronic disease seen by allergist-immunologists, has both dermatologic and ocular manifestations. The ocular component is often disproportionately higher than the dermatologic disease. Even if skin abnormalities seem well controlled, these patients require ophthalmic evaluation. Atopic keratoconjunctivitis in atopic dermatitis patients is characterized by acute exacerbations and requires maintenance therapy for long-term control. Future studies will continue to emphasize the use of steroid-sparing, immunomodulating agents that have the potential to provide long-lasting anti-inflammatory control with a more favorable side-effect profile.
Ophthalmic Plastic and Reconstructive Surgery | 2013
David B. Samimi; Brett P. Bielory; Darlene Miller; Thomas E. Johnson
Purpose: To investigate microbiologic trends and role of biofilm on periorbital biomaterials surgically explanted for recalcitrant infection. Methods: A search of the Bascom Palmer Eye Institute, University of Miami Miller School of Medicine microbiology laboratory electronic database was conducted from 1980 to 2010. Culture results were analyzed from submitted periorbital biomaterials explanted for nonresolving infections or exposure. Random select samples cultured during the study were sent for electron microscopy. Results: Twenty-one explanted biomaterials were identified from 18 patients. Five orbital plate implants included 2 made of nylon, 1 of porous polyethylene, 1 of silicone, and 1 metallic. Of 4 anophthalmic socket sphere implants, 2 were silicone, 1 was porous polyethylene, and 1 was poly-2-hydroxyethyl methacrylate. Lacrimal intubation devices included 10 silicone stents and 2 pyrex glass Jones tubes. All biomaterials were culture positive with 40 total isolates identified. The most common organisms overall were Mycobacterium chelonae (N = 9), Staphylococcus aureus (N = 8), and Pseudomonas aeruginosa (N = 3). One hundred percent of orbital spheres had Gram-positive organisms, 90% of lacrimal silicone stents grew atypical mycobacterium, and 60% of orbital plates were culture positive for yeast species. Mixed organism growth was documented on 58% of the specimens. Ten of 12 implants (83%) examined with electron microscopy exhibited organisms encased in glycocalyx, suggestive of biofilm. Conclusions: A diverse array of microorganisms can colonize biomaterials implanted within the orbit and lacrimal drainage system. The authors’ study showed that the majority of infected periocular and orbital alloplastic implants display biofilm when studied with electron microscopy (83%). The cultured organism type depended on the implant location and composition. Most infected silicone lacrimal stents grew atypical mycobacterium, whereas infected orbital fracture repair plates demonstrated yeast species. Biofilms are known to be antibiotic resistant, explaining the need to explant most infected alloplastic implants. Further research concerning treatment of biofilms may prevent explantation and improve surgical outcomes.
Current Opinion in Allergy and Clinical Immunology | 2010
Brett P. Bielory; Victor L. Perez; Leonard Bielory
Purpose of reviewCorticosteroids are an effective short-term treatment option for seasonal allergic conjunctivitis (SAC). Their use has been limited due to their side effects and has led to the development of modified ‘soft’, ‘smart’ ophthalmic corticosteroid formulations that retain their anti-inflammatory mechanism of action with an improved safety profile. Recent findingsSimilar to the development of the prodrug concept for the nose and lung that led to the development of ciclesonide, a chloromethyl-ester group substitution at the carbon-20 (C-20) position of the traditional corticosteroid has led to the development of a family of potential ophthalmic corticosteroids including loteprednol etabonate that has demonstrated similar efficacy to the C-20 ketone corticosteroids in the treatment of the signs and symptoms of ocular allergies, but less likely to induce elevations in intraocular pressure (IOP) or the formation of cataracts. The C-20 ester corticosteroid, loteprednol etabonate has been designed to be rapidly converted to an inactive, nontoxic metabolite, thus minimizing adverse effects, and loteprednol etabonate (0.2%) is currently the only ophthalmic corticosteroid specifically developed for and approved by the Food and Drug Administration for treatment of SAC. SummaryThe development of modified or soft, smart corticosteroids such as loteprednol etabonate provides an avenue for expanding the treatment of the inflammation associated with signs and symptoms in patients with chronic forms or severe acute exacerbations of allergic conjunctivitis. Modified corticosteroids are an effective and well tolerated option for the short-term treatment of the inflammation and signs and symptoms associated with SAC.
Current Opinion in Allergy and Clinical Immunology | 2011
Brett P. Bielory; Terrence P. O’Brien
Purpose of reviewThis article reviews the complications of laser-assisted in-situ keratomileusis (LASIK) associated with ocular allergy. This review will provide guidance and heighten the need for a more comprehensive allergic evaluation before recommending LASIK procedure to patients. The material provided allows enhanced awareness of the potential postsurgical effects on allergic responses of the ocular surface and management thereof. Recent findingsOcular allergy is often underdiagnosed and has been previously reported only in a handful of peer-reviewed journals as the cause for ocular irritation and visual morbidity in post-LASIK dry eye disease. Diffuse lamellar keratitis is one complication of LASIK that has been linked to atopic individuals. LASIK causes significant inflammation in normal eyes, which is only exacerbated in atopic patients. Atopy may be a contributing factor in patients with patients with post-LASIK dry eye symptoms. Further investigation is required to better understand the complications of LASIK in allergic patients. SummaryLASIK surgery has been associated with increased anterior surface inflammatory processes that include dry eye syndromes and ocular allergy. In addition, poorer outcomes of LASIK procedures have been reported in patients with moderate to severe ocular allergies and chronic forms of allergic conjunctivitis, which is an absolute contraindication to the LASIK procedure. We propose preoperative and postoperative management algorithms for allergic LASIK candidates.
Archives of Ophthalmology | 2012
Brett P. Bielory; David R. Jacobs; Eduardo C. Alfonso; Victor L. Perez; Sander R. Dubovy; Audina M. Berrocal
ever, any study of the effects of -blocker therapy must address the fragility of the patients to be tested and possible systemic and ocular adverse effects. Nevertheless, if topical -blockers prove to be effective in preventing some cases of ROP, this opens the door for a more individualized approach to prevention of the disease, eg, using -adrenergic receptor polymorphisms to guide ROP management.
Archives of Ophthalmology | 2011
Brett P. Bielory; Hamed Bazargan Lari; Neena Mirani; Rajendra Kapila; Valerie A. Fitzhugh; Roger E. Turbin
tergent. The detergent may enable the toxin to penetrate deeper into the cornea. We believe that these are the first reported cases of Surgilube use on the ocular surface. Because of the common use of Surgilube in the hospital setting and the similar appearance to certain ocular medications, it is unlikely that this is the first actual time its mistaken use has occurred. It is important to correctly identify any medication being used on the ocular surface. It is also important to identify which medications are safe for use in the eye and not to use medications that do not have this designation. Although the patients in our case reports regained good vision, one patient was left with corneal haze and the other with chronic dry eye irritation. Due to the slow reepithelialization of the cornea, infectious keratitis and loss of visual acuity are possible.
Current Opinion in Allergy and Clinical Immunology | 2016
Brett P. Bielory; Steven P. Shah; Terrence P. O'Brien; Victor L. Perez; Leonard Bielory
Purpose of reviewThe present review provides an overview on the potential of different systemic and topical treatments in chronic forms of ocular allergy and dry eye disorder (DED). The impact on anterior surface of ocular inflammatory disorder encompasses an array of conditions, which are frequently underreported. This can contribute to underdiagnoses and ineffective management from healthcare providers such as an allergist and/or ophthalmologist who routinely provide care for these common disorders. Owing to the current limited therapeutic options, healthcare providers are routinely seeking alternative treatments that could facilitate effective management of the conditions. Recent findingsRecent advances in immunopathophysiology of ocular surface disorders has provided new potential targets and therapeutic strategies for the treatment of DED and ocular allergy that may include various immunobiological modulators. These modulators have focused on regulating the Th1 and Th2 immune-mediated inflammatory pathways that inhibit various cytokines (e.g. IL-1, IL-4, IL-5, IL-9, IL-13) antibodies (e.g. IgE), and other surface markers of various cell lines (e.g. activated T-lymphocytes, lymphocyte function-associated antigen-1). SummaryRecent findings about the pathophysiology of DED and ocular allergy have led to the greater understanding of the molecular and cellular mechanisms of ocular surface diseases leading to the potential novel targets for immunomodulation of anterior surface ocular disorders. New topical glucocorticoids, leukotriene receptor antagonists, IL-1 antagonists, IL-5, IL-4/IL-13 antagonists, integrin antagonists, and quinolone derivatives appear to be encouraging.
Current Opinion in Allergy and Clinical Immunology | 2014
Brett P. Bielory; Leonard Bielory
Purpose of reviewTo provide opinions on the potential impact of increasing use of steroids by various formulations, as recent approvals have switched intranasal steroids to over-the-counter (OTC) status. Systemic glucocorticosteroids are the predominant formulations available only by prescription, whereas low-dose dermatological formulations are also available OTC. The recently approved OTC intranasal steroid has generated questions on their potential adverse effects, especially on the eye. Recent findingsOral and ophthalmic steroids have the most potent impact on the development of increased intraocular pressure (IOP) and lens opacifications (ILO), but other factors such as age, race and comorbidities (e.g. hypertension, diabetes and smoking) also play a role. There are no biomarkers that have been established to identify populations at additional risk. However, individuals of Caribbean, African, Hispanic or Asian ancestry have a higher predilection for the development of glaucoma and thus may be predisposed to IOP. ILO has been noted to have a slight increase with intranasal corticosteroids, but no specific correlations with the development of cataracts. SummaryThe OTC placement of intranasal steroid may cause a subset of genetically sensitive individuals to earlier development of IOP and ILO, but the socioeconomic benefit for patients with allergies having access to the ‘OTC open formulary’ appears to warrant consideration with caveats of monitoring the effect at large, especially in susceptible populations such as those with a family history or specific ancestries.